贝伐珠单抗联合化疗对晚期结直肠癌患者治疗效果的影响  

Effect of Bevacizumab Combined with Chemotherapy on Patients with Advanced Colorectal Cancer

作　　者：孙旋 SUN Xuan(Department of Oncology,NO.6 People's Hospital of Xuzhou,Xuzhou,Jiangsu,221000,China)

机构地区：[1]徐州市第六人民医院肿瘤科,江苏徐州221000

出　　处：《中外医疗》2025年第7期76-79,共4页China & Foreign Medical Treatment

摘　　要：目的探讨贝伐珠单抗联合化疗在晚期结直肠癌患者中的治疗效果。方法回顾性选取2022年1月—2023年12月徐州市第六人民医院收治的64例晚期结直肠癌患者的临床资料,根据不同的治疗方法将其分为两组,每组32例。化疗组采用常规化疗方案治疗(奥沙利铂+卡培他滨方案),联合组在化疗组的基础上联合贝伐珠单抗治疗,两组均完成3个周期(21 d为1个周期)治疗,对比两组患者的疾病控制情况、血清肿瘤标志物水平及不良反应发生情况。结果联合组疾病控制率为90.63%(29/32),高于化疗组的68.75%(22/32),差异有统计学意义(χ^(2)=4.730,P<0.05)。治疗后,联合组血清癌胚抗原、糖类抗原19-9、糖类抗原24-2、糖类抗原72-4水平均低于化疗组,差异均有统计学意义(P均<0.05)。两组不良反应总发生率对比,差异无统计学意义(P>0.05)。结论对于确诊为晚期结直肠癌的患者,贝伐珠单抗联合化疗治疗可取得较为理想的治疗效果,可进一步改善其血清肿瘤标志物水平,未增加不良反应的发生。Objective To investigate the therapeutic effect of bevacizumab combined with chemotherapy in patients with advanced colorectal cancer.Methods The clinical data of 64 patients with advanced colorectal cancer admitted to NO.6 People's Hospital of Xuzhou from January 2022 to December 2023 were retrospectively selected and divided into two groups according to different treatment methods,with 32 cases in each group.The chemotherapy group was treated with conventional chemotherapy(oxaliplatin and capecitabine regimen);the combined group was treated with bevacizumab on the basis of the chemotherapy group.Both groups completed 3 cycles of treatment(21 for 1 cycle).The disease control,serum tumor marker level and incidence of adverse reactions were compared between the two groups.Results The disease control rate of the combined group was 90.63%(29/32)higher than that of the chemotherapy group 68.75%(22/32),and the difference was statistically significant(χ^(2)=4.730,P<0.05).After treatment,the levels of serum carcinoembryonic antigen,carbohydrate antigen 19-9,carbohydrate antigen 24-2 and carbohydrate antigen 72-4 in the combined group were lower than those in the chemotherapy group,and the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients diagnosed with advanced colorectal cancer,bevacizumab combined with chemotherapy can achieve an ideal therapeutic effect,which can further improve the level of serum tumor markers without increasing the incidence of adverse reactions.

关 键 词：晚期结直肠癌 化疗 贝伐珠单抗 奥沙利铂 卡培他滨 肿瘤标志物 

分 类 号：R735[医药卫生—肿瘤]